This company listing is no longer active
MorphoSys Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Arkadius Pichota
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | less than a year |
Board average tenure | 6.5yrs |
Recent management updates
Recent updates
CEO
Arkadius Pichota
less than a year
Tenure
Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Legal and Human Resources Officer & Member of Management Board | 4.6yrs | €1.10m | 0.0036% € 90.9k | |
Chief Executive Officer | less than a year | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Research & Development Officer | 1.8yrs | no data | no data | |
Head of Accounting & Tax | no data | no data | no data | |
Head of Discovery Alliances & Technologies | no data | no data | no data | |
Head of Investor Relations | no data | no data | no data | |
Chief Business Officer | no data | no data | no data | |
Head of Technical Operations | no data | no data | no data | |
Head of Alliance Management | no data | no data | no data | |
Head of Clinical Operations | no data | no data | no data | |
Head of Business Team | no data | no data | no data |
1.0yrs
Average Tenure
Experienced Management: MOR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
Independent Member of Supervisory Board | 5.2yrs | €92.60k | no data | |
Chairman of the Supervisory Board | less than a year | no data | no data | |
Member of the Supervisory Board | less than a year | no data | no data | |
Deputy Chairman of the Supervisory Board | less than a year | no data | no data |
6.5yrs
Average Tenure
51yo
Average Age
Experienced Board: MOR's board of directors are considered experienced (6.5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/08/05 22:09 |
End of Day Share Price | 2024/08/05 00:00 |
Earnings | 2024/03/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MorphoSys AG is covered by 35 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Olav Zilian | Baader Helvea Equity Research |
Brian Balchin | Barclays |
Rosie Turner | Barclays |